Dejan Micic to Infliximab
This is a "connection" page, showing publications Dejan Micic has written about Infliximab.
Connection Strength
0.916
-
Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372.
Score: 0.581
-
Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017 Jun; 32(6):1143-1151.
Score: 0.146
-
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.
Score: 0.143
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.045